In this study, using a short duration of treatment with high concentration of gefitinib, we established a unique model to obtain gefitinib‐resistant persisters (GRPs) of EGFR‐mutant NSCLC with stem cell features, in vitro as well as in vivo. This evidence concerns the gene EGFR and non-small cell lung carcinoma.